Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28541816 | 0.84 | TDP1 (0.60) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL1343814 | 0.83 | TDP1 (0.64) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL16960055 | 0.83 | TDP1 (0.64) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL28343320 | 0.82 | TDP1 (0.52) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL472112 | 0.81 | TDP1 (1.00) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL25310 | 0.79 | HSD17B10 (0.50) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL3345170 | 0.78 | TDP1 (0.48) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL55225 | 0.78 | GPR35 (0.55) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL10825048 | 0.77 | TDP1 (0.47) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL5682648 | 0.77 | GPR35 (0.67) | TDP1TSHRSMN1; SMN2GPR35L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824517-A | A kind of 3- nitro o xylene oxidation is the clean preparation method of 2- methyl-3-nitro benzoic acid | 江苏永安化工有限公司 | 2019-05-31 | — | — | CN | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| CN-1491216-A | Novel alkylphenylimidazolidine derivatives for the treatment of urinary incontinence | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| EP-0833818-A1 | CB 2? RECEPTOR AGONIST COMPOUNDS | SANOFI (FR) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000860-A1 | CB2 RECEPTOR AGONIST COMPOUNDS | SANOFI (FR) | 1997-01-09 | — | — | WO | disclosed |
| EP-0041043-A1 | Process for the preparation of derivatives of alkenyl benzene or alkenyl naphthalene | CIBA-GEIGY AG (CH) | 1981-12-02 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | TDP1 2797/4885TSHR 1456/4885SMN1; SMN2 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.